Press Releases

Company News
Summary ToggleAcura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology
Dec 14, 2016

FDA Provides Advice on Further Development of LTX-04

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2016 Financial Results
Nov 14, 2016
PALATINE, IL -- (Marketwired) -- 11/14/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2016 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15, 2016
Nov 09, 2016
PALATINE, IL -- (Marketwired) -- 11/09/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2016 following the close of financial markets on

Read more

Summary ToggleKemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent Technology
Oct 18, 2016

Agreement focused on KemPharm's current and in-development IR Opioid Pipeline

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2016 Financial Results
Aug 08, 2016
PALATINE, IL -- (Marketwired) -- 08/08/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2016 . The Company reported a net loss of $3.3 million for

Read more

Summary ToggleAcura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400
Jul 11, 2016

Data Supports Effectiveness of LIMITX(TM) Technology to Address Oral Opioid Abuse

Read more

Summary ToggleAcura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities
Jun 08, 2016

Topline Results From Study AP-LTX-400 Cohort 2

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2016 Financial Results
May 02, 2016
PALATINE, IL -- (Marketwired) -- 05/02/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016 . The Company reported net loss of $3.4 million for the first

Read more

Summary ToggleIndiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem
Apr 28, 2016

Indiana-Based Acura Pharmaceuticals Commends Law Providing Pharmacists Additional Tools to Address Meth Production and Abuse

Read more

Summary ToggleAcura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology
Apr 26, 2016

New Oral Opioid Abuse Technology

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016
Apr 21, 2016
PALATINE, IL -- (Marketwired) -- 04/21/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence
Apr 13, 2016

Conference Call and Webcast Scheduled to Discuss Results on Thursday, April 14, 2016

Read more

Summary ToggleAcura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04
Apr 12, 2016

Lead LIMITX Oral Abuse Deterrent Development Program

Read more

Summary ToggleAcura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective
Mar 30, 2016
PALATINE, IL -- (Marketwired) -- 03/30/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) today announced that its universal shelf registration statement on Form S-3, as amended, was declared effective by the Securities and Exchange Commission (SEC) today.

Read more

Summary ToggleAcura Pharmaceuticals Acknowledges Inclusion of Meth-Resistant Technology in Indiana Legislation
Mar 14, 2016

Indiana Recognizes the Role Meth-Resistant Products Play in Addressing Local Meth Production

Read more

Summary ToggleAcura Pharmaceuticals to Present at the 28th Annual ROTH Conference
Mar 08, 2016
PALATINE, IL -- (Marketwired) -- 03/08/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones , President and Chief Executive Officer, will present at the 28 th

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results
Feb 29, 2016
PALATINE, IL -- (Marketwired) -- 02/29/16 --  Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2015 .

Read more

Summary ToggleAcura Pharmaceuticals to Host 2015 Financial Results Conference Call on March 1, 2016
Feb 22, 2016
PALATINE, IL -- (Marketwired) -- 02/22/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for 2015 following the close of financial markets on Monday, February

Read more

Displaying 19 - 36 of 136 results